- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
Michael A. Weber, MD, on aprocitentan approval: A new approach to managing hypertension
Michael A. Weber, MD, an investigator in the PRECISION study, discusses the newly FDA approved drug aprocitentan (Tryvio), and its promise for helping patients with treatment-resistant hypertension.
On March 20, 2024, The US Food and Drug Administration (FDA) approved aprocitentan (Tryvio) as concomitant treatment for hypertension in adults whose blood pressure (BP) is not adequately controlled by other medications.
Tryvio, from drugmaker Idorsia, is the first antihypertensive therapy to be approved in nearly 4 decades that delivers its BP-lowering effect through a novel mechanism of action. The drug will be available to patients in the second half of 2024, the company said.
To learn more about this new once-daily oral medication and what physicians need to know about it, PatientCareOnline sat down with Michael A. Weber, MD, Professor of Medicine, Division of Cardiovascular Medicine State University of New York, and an investigator in the PRECISION study that evaluated aprocitentan.
